This article is more than 5 years old. Information may no longer be current.

Despite lack of industry support, CATT will continue as planned

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — In response to inquiries over the status of the much anticipated bevacizumab vs. ranibizumab study, the lead investigator said the study was on track.

Daniel F. Martin, MD, delivered an update on funding for the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT ) during Retina Subspecialty Day preceding the American Academy of Ophthalmology annual meeting. A recently revised Medicare policy will support the use of ranibizumab in the trial, and patients will have no out-of-pocket expense, he said.

Genentech decided in July not to support the study or supply either of the drugs, he said.

"Despite numerous inquiries, we have been told that that decision is irreparable," Dr. Martin said. However, "we are unaffected by the ... decision," he said, reiterating that CATT is fully funded and ready to begin.

In CATT, Dr. Martin and colleagues will prospectively compare the results of 1,200 patients randomly assigned to receive either bevacizumab or ranibizumab. Enrollment is expected to begin in early 2008, with 1-year results released in early 2010.